About Quarterly Earnings Report Disclosures
| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥35.25B | ¥32.37B | +8.9% |
| Cost of Sales | ¥8.18B | ¥16.46B | -50.3% |
| Gross Profit | ¥8.17B | ¥15.91B | -48.6% |
| SG&A Expenses | ¥6.41B | ¥12.56B | -48.9% |
| Operating Income | ¥2.65B | ¥3.35B | -20.8% |
| Non-operating Income | ¥154M | ¥204M | -24.5% |
| Non-operating Expenses | ¥99M | ¥238M | -58.4% |
| Ordinary Income | ¥2.66B | ¥3.31B | -19.7% |
| Profit Before Tax | ¥1.81B | ¥3.31B | -45.3% |
| Income Tax Expense | ¥539M | ¥752M | -28.3% |
| Net Income | ¥1.27B | ¥2.56B | -50.3% |
| Net Income Attributable to Owners | ¥2.23B | ¥2.56B | -13.0% |
| Total Comprehensive Income | ¥1.83B | ¥2.75B | -33.2% |
| Depreciation & Amortization | ¥1.35B | ¥1.07B | +26.8% |
| Interest Expense | ¥11M | ¥22M | -50.0% |
| Basic EPS | ¥78.49 | ¥90.36 | -13.1% |
| Dividend Per Share | ¥25.00 | ¥25.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥55.66B | ¥58.05B | ¥-2.39B |
| Cash and Deposits | ¥6.41B | ¥10.60B | ¥-4.19B |
| Accounts Receivable | ¥16.10B | ¥15.18B | +¥916M |
| Inventories | ¥15.50B | ¥14.76B | +¥742M |
| Non-current Assets | ¥47.29B | ¥42.49B | +¥4.81B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥1.10B | ¥1.16B | ¥-54M |
| Financing Cash Flow | ¥1.38B | ¥-2.41B | +¥3.79B |
| Item | Value |
|---|---|
| Net Profit Margin | 6.3% |
| Gross Profit Margin | 23.2% |
| Current Ratio | 251.3% |
| Quick Ratio | 181.3% |
| Debt-to-Equity Ratio | 0.46x |
| Interest Coverage Ratio | 240.82x |
| EBITDA Margin | 11.4% |
| Effective Tax Rate | 29.7% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +8.9% |
| Operating Income YoY Change | -20.8% |
| Ordinary Income YoY Change | -19.7% |
| Net Income Attributable to Owners YoY Change | -13.0% |
| Total Comprehensive Income YoY Change | -33.1% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 28.76M shares |
| Treasury Stock | 367K shares |
| Average Shares Outstanding | 28.37M shares |
| Book Value Per Share | ¥2,556.48 |
| EBITDA | ¥4.00B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥25.00 |
| Year-End Dividend | ¥30.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| AnimalHealth | ¥3.77B | ¥282M |
| Oversea | ¥2.13B | ¥132M |
| Pharmaceutical | ¥29.25B | ¥3.12B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥71.00B |
| Operating Income Forecast | ¥6.00B |
| Ordinary Income Forecast | ¥6.00B |
| Net Income Attributable to Owners Forecast | ¥5.00B |
| Basic EPS Forecast | ¥176.22 |
| Dividend Per Share Forecast | ¥28.00 |
This data was automatically extracted from XBRL files. Please refer to the original disclosure documents for accuracy.
| Property, Plant & Equipment | ¥19.84B | ¥18.71B | +¥1.13B |
| Intangible Assets | ¥6.57B | ¥6.99B | ¥-421M |
| Goodwill | ¥4.11B | ¥4.36B | ¥-251M |
| Investment Securities | ¥16.37B | ¥12.33B | +¥4.04B |
| Total Assets | ¥108.77B | ¥103.89B | +¥4.88B |
| Current Liabilities | ¥22.15B | ¥22.88B | ¥-729M |
| Accounts Payable | ¥5.66B | ¥6.41B | ¥-750M |
| Short-term Loans | ¥4.24B | ¥4.46B | ¥-222M |
| Non-current Liabilities | ¥11.57B | ¥8.46B | +¥3.11B |
| Long-term Loans | ¥9.53B | ¥6.44B | +¥3.09B |
| Total Liabilities | ¥33.72B | ¥31.34B | +¥2.38B |
| Total Equity | ¥72.59B | ¥71.56B | +¥1.04B |
| Capital Stock | ¥1.20B | ¥1.20B | ¥0 |
| Capital Surplus | ¥31M | - | - |
| Retained Earnings | ¥59.94B | ¥59.55B | +¥394M |
| Treasury Stock | ¥-704M | ¥-704M | ¥0 |
| Owners' Equity | ¥66.86B | ¥65.31B | +¥1.55B |
| Working Capital | ¥33.51B | - | - |